Αρχική World News Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for... World News Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors Από Ogkologos - 24 Σεπτεμβρίου, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... 21 Απριλίου, 2021 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... 15 Ιουνίου, 2022 Getting cancer services back on track during the COVID-19 pandemic 22 Ιουνίου, 2020 Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... 10 Αυγούστου, 2022 Φόρτωση περισσοτέρων HOT NEWS Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &...